Clinical Trial Update: Neoadjuvant Bev Plus DOF vs DOF in LAGC and Its Association With Circulating Tumor Cell [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial tested neoadjuvant bevacizumab added to DOF versus DOF alone in locally advanced gastric carcinoma. The study has completed and examined the a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• DOF

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Locally Advanced Gastric Carcinoma | Phase 1, Phase 2 | Status: COMPLETED